Exelixis Inc (EXEL) Stock Price, Quote & News

Company Profile

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosin...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 837 7000

Fax: 650 837 8300

Website: www.exelixis.com

Address:

1851 Harbor Bay Parkway, Alameda, United States

SuperGreenToday Feb. 20 at 8:14 PM

$EXEL Share Price: $43.62 Contract Selected: Aug 21, 2026 $45 Calls Buy Zone: $3.40 – $4.20 Target Zone: $5.62 – $6.87 Potential Upside: 56% ROI Time to Expiration: 181 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

AdamURAtoFookingNeptune Feb. 20 at 3:39 PM

$EXEL the most boring trade I’ve ever put on? 🤔 close

0 · Reply

Doozio Feb. 20 at 4:28 AM

Out of da chop chop wen 🐑 confidence is low da 🧠 shall $EXEL with da huckleberries thru da $$$$$$. 🐒🍌🧠⏰♾️

0 · Reply

Reanimated666 Feb. 17 at 12:39 PM

$EXEL Going and goes no where

2 · Reply

OfficialStocktwitsUser Feb. 17 at 1:08 AM

$EXEL RSI: 51.81, MACD: -0.1434 Vol: 0.88, MA20: 43.29, MA50: 43.59 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

1 · Reply

BullRun4 Feb. 13 at 6:46 PM

$EXEL Look at CRDF Cardiff Oncology

0 · Reply

OS2020 Feb. 12 at 7:29 AM

$EXEL https://finance.yahoo.com/news/fda-review-zanzalintinib-combo-highlights-021342741.html

0 · Reply

erevnon Feb. 11 at 4:23 PM

Stifel maintains Exelixis $EXEL at Hold and raises the price target from $43 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

ZacksResearch Feb. 11 at 3:09 PM

$EXEL smashes Q4 earnings expectations but shares dip. Why? 🤔 📈 EPS of 94 cents beats estimates of 77 cents, driven by lower operating expenses and ongoing share buybacks. 📊 Revenues up 5.6% YoY to $598.7 million, surpassing estimates with Cabometyx marginally beating its sales target. See what’s next for Exelixis and its promising pipeline 👉 https://www.zacks.com/stock/news/2854214/exel-q4-earnings-and-revenues-beat-colorectal-cancer-drug-in-focus?cid=sm-stocktwits-2-2854214-body-32996&ADID=SYND_STOCKTWITS_TWEET_2_2854214_BODY_32996

0 · Reply

ZacksResearch Feb. 11 at 2:09 PM

$EXEL just put up a clean Q4 beat — and management isn’t slowing down. Earnings and revenues topped estimates, new buybacks are boosting momentum, Cabometyx sales climbed, and zanzalintinib advances toward FDA review. That’s growth plus capital return — a powerful combo. See what’s driving the bullish setup here 👉 https://www.zacks.com/stock/news/2854214/exel-q4-earnings-and-revenues-beat-colorectal-cancer-drug-in-focus?cid=sm-stocktwits-2-2854214-teaser-32995&ADID=SYND_STOCKTWITS_TWEET_2_2854214_TEASER_32995

0 · Reply

Exelixis, Inc. (EXEL) Q4 2025 Earnings Call Transcript

Feb 10, 2026, 4:05 PM EST - 12 days ago

Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

Feb 2, 2026, 8:00 AM EST - 21 days ago

Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer

Jan 28, 2026, 10:06 PM EST - 25 days ago

Exelixis: Stock Likely To Go Higher On A Possible Key FDA Approval

Jan 27, 2026, 4:05 PM EST - 26 days ago

Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026

Jan 22, 2026, 7:22 AM EST - 4 weeks ago

Exelixis: High-Growth Oncology Name Trading At A Discount

Jan 13, 2026, 12:45 AM EST - 5 weeks ago

Exelixis, Inc. (EXEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 11, 2026, 4:00 PM EST - 6 weeks ago

Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026

Jan 7, 2026, 8:00 AM EST - 6 weeks ago

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

NTRA

Jan 6, 2026, 4:05 PM EST - 6 weeks ago

Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026

Dec 31, 2025, 12:46 PM EST - 7 weeks ago

See How Rare Bullish Inflows Lift Outliers Like Exelixis

Dec 11, 2025, 6:12 AM EST - 2 months ago

Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day Transcript

Dec 3, 2025, 4:05 PM EST - 2 months ago

Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025

Nov 10, 2025, 1:41 PM EST - 3 months ago

Exelixis, Inc. (EXEL) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

Nov 6, 2025, 9:39 PM EST - 3 months ago

Exelixis: The STELLAR Win Is A Mixed Bag, But Things Look Positive Still

Nov 6, 2025, 4:05 PM EST - 3 months ago

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

Nov 4, 2025, 9:06 PM EST - 3 months ago

Exelixis, Inc. (EXEL) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:05 PM EST - 3 months ago

Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 21, 2025, 4:05 PM EDT - 4 months ago

Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Oct 20, 2025, 10:48 AM EDT - 4 months ago

Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results

Oct 20, 2025, 2:30 AM EDT - 4 months ago

Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet

Oct 18, 2025, 3:00 AM EDT - 4 months ago

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025

Sep 24, 2025, 12:33 PM EDT - 5 months ago

Exelixis, Inc. (EXEL) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 10:20 AM EDT - 5 months ago

Exelixis, Inc. (EXEL) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 9, 2025, 1:06 PM EDT - 5 months ago

Exelixis, Inc. (EXEL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 4, 2025, 10:06 AM EDT - 6 months ago

EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm

Sep 3, 2025, 7:43 PM EDT - 6 months ago

Exelixis, Inc. (EXEL) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 3:43 PM EDT - 6 months ago

Exelixis, Inc. (EXEL) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)

Aug 29, 2025, 5:47 PM EDT - 6 months ago

Exelixis Announces Appointment of Dana T. Aftab, Ph.D.

Aug 27, 2025, 4:05 PM EDT - 6 months ago

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

Aug 25, 2025, 6:01 PM EDT - 6 months ago

Exelixis: RCC Stronghold, NET Launch, And A CRC Readout That Matters

Jul 31, 2025, 12:27 PM EDT - 7 months ago

Exelixis: Zanzalintinib Sees Mixed Progress, Cabozantinib Grinds Upwards

Jul 29, 2025, 12:32 PM EDT - 7 months ago

Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans

Jul 28, 2025, 10:51 PM EDT - 7 months ago

Exelixis, Inc. (EXEL) Q2 2025 Earnings Call Transcript

Jul 28, 2025, 4:05 PM EDT - 7 months ago

Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 24, 2025, 5:04 PM EDT - 7 months ago

Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Jul 14, 2025, 4:05 PM EDT - 7 months ago

Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025

Jun 23, 2025, 12:58 PM EDT - 8 months ago

Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment

Jun 23, 2025, 10:37 AM EDT - 8 months ago

Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars

Jun 22, 2025, 5:00 PM EDT - 8 months ago

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

Jun 20, 2025, 6:54 AM EDT - 8 months ago

Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

May 23, 2025, 6:25 AM EDT - 9 months ago

Product Performance, Big Money Lift Exelixis

May 22, 2025, 5:17 PM EDT - 9 months ago

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

May 22, 2025, 4:05 PM EDT - 9 months ago

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June

May 14, 2025, 2:53 PM EDT - 10 months ago

Exelixis: A Notable Quarter

May 14, 2025, 10:44 AM EDT - 10 months ago

Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidance

May 13, 2025, 8:31 PM EDT - 10 months ago

Exelixis, Inc. (EXEL) Q1 2025 Earnings Call Transcript

SuperGreenToday Feb. 20 at 8:14 PM

0 · Reply

AdamURAtoFookingNeptune Feb. 20 at 3:39 PM

$EXEL the most boring trade I’ve ever put on? 🤔 close

0 · Reply

Doozio Feb. 20 at 4:28 AM

Out of da chop chop wen 🐑 confidence is low da 🧠 shall $EXEL with da huckleberries thru da $$$$$$. 🐒🍌🧠⏰♾️

0 · Reply

Reanimated666 Feb. 17 at 12:39 PM

$EXEL Going and goes no where

2 · Reply

OfficialStocktwitsUser Feb. 17 at 1:08 AM

1 · Reply

BullRun4 Feb. 13 at 6:46 PM

$EXEL Look at CRDF Cardiff Oncology

0 · Reply

OS2020 Feb. 12 at 7:29 AM

$EXEL https://finance.yahoo.com/news/fda-review-zanzalintinib-combo-highlights-021342741.html

0 · Reply

erevnon Feb. 11 at 4:23 PM

Stifel maintains Exelixis $EXEL at Hold and raises the price target from $43 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

ZacksResearch Feb. 11 at 3:09 PM

0 · Reply

ZacksResearch Feb. 11 at 2:09 PM

0 · Reply

crumpy1 Feb. 11 at 2:01 PM

$EXEL where is the volume? 800 shares premarket

0 · Reply

OS2020 Feb. 11 at 12:30 PM

$EXEL pushing in PM down to hit the stop losses ... we see $45 today

0 · Reply

BusinessStock Feb. 11 at 12:05 PM

$EXEL Turn green..

0 · Reply

BusinessStock Feb. 11 at 11:02 AM

$EXEL

0 · Reply

justiceforb_85 Feb. 10 at 9:23 PM

$EXEL pretty solid earnings and great expectations for zanzalintinib including possible FDA approval this year.

2 · Reply

StocktwitsEarnings Feb. 10 at 9:15 PM

$EXEL Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.92 up 87.76% YoY • Reported revenue of $598.66M up 5.63% YoY • Exelixis is maintaining its 2026 financial guidance, projecting total revenues between $2.53B and $2.63B, with net product revenues of $2.33B to $2.43B and an effective tax rate of 21% to 23%.

0 · Reply

OtherOtttawaGuy Feb. 10 at 9:09 PM

$EXEL Press Release Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update February 10, 2026 – Total Revenues of $599 million for the Fourth Quarter of 2025, $2.320 billion for the Fiscal Year 2025 – – Cabozantinib Franchise Achieved $2.123 billion in U.S. Net Product Revenues for the Fiscal Year 2025, including $547 million for the Fourth Quarter of 2025 – – GAAP Diluted EPS of $0.88 for the Fourth Quarter of 2025, $2.78 for the Fiscal Year 2025 – – Conference Call and Webcast Today at 5:00 PM Eastern Time –

0 · Reply

BusinessStock Feb. 10 at 7:54 PM

$EXEL

1 · Reply

Estimize Feb. 10 at 4:00 PM

$EXEL reports after the close, Estimize Consensus +0.02 EPS and +17.35M Revs compared to WS http://www.estimize.com/exel/fq4-2025?utm_conte

0 · Reply

DefenseMania Feb. 10 at 12:19 PM

$EXEL earnings today 🚀🚀🚀🙏🏻 CEO doing everything right

0 · Reply

ZacksResearch Feb. 9 at 2:30 PM

$EXE, $AR, and $EE are set to ride the natural gas wave! 🌊 ⚡️ Record 360 Bcf storage draw flips inventories to a deficit, raising price sensitivity. 📈 Expand Energy emerges as the largest U.S. nat gas producer post-merger, with a 29.5% EPS growth forecast for 2026. Discover why these stocks could shine in a tightening market 👉 $EXEL https://www.zacks.com/stock/news/2841113/does-the-record-gas-draw-support-a-bullish-case-for-investors?cid=sm-stocktwits-2-2841113-body-32552&ADID=SYND_STOCKTWITS_TWEET_2_2841113_BODY_32552

0 · Reply

NorthStarStats Feb. 9 at 3:45 AM

$ESS (100) Mediocre -Sideways Chop, $SF (100) Poor - Good Trend, $JPM (100) Poor- Good Trend, $UAL (95) Poor- Good Trend, $EXEL (85) Poor - Sideways Chop

0 · Reply

Market Cap	11.33B
Revenue (ttm)	2.32B
Net Income (ttm)	782.57M
EPS (ttm)	N/A
PE Ratio	16.18
Forward PE	14.47
Profit Margin	33.73%
Debt to Equity Ratio	0.00

Volume	1,046,574
Avg Vol	2,607,626
Day's Range	N/A - N/A
Shares Out	259.71M
Stochastic %K	72%
Beta	0.42
Analysts	Sell
Price Target	$47.11